0001104659-24-056402.txt : 20240502 0001104659-24-056402.hdr.sgml : 20240502 20240502161629 ACCESSION NUMBER: 0001104659-24-056402 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mirza Nadeem Q. CENTRAL INDEX KEY: 0002021015 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 24908526 MAIL ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 BUSINESS PHONE: 617-463-9385 MAIL ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 4 1 tm2413094-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-01 0 0001781983 Aprea Therapeutics, Inc. APRE 0002021015 Mirza Nadeem Q. 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-05-01 4 A 0 6730 0.00 A 6730 D Stock Options (Right to Purchase) 5.25 2024-05-01 4 A 0 26920 0.00 A 2034-05-01 Common Stock 29920 26920 D These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. /s/ John Hamill, as Attorney-in-Fact 2024-05-02